Search

In this study we tested functionalized AuNPs as an improved drug delivery tool in pancreatic and colon cancer cell lines AR42J and HT-29, using radioimmunoassay method. Ga radiolabeled DOTA-Tyr(3)-octreotide, DOTA-NaI(3)-octreotide and DOTA-NT peptides were linked on nanoparticles surface, aiming to increase the peptide density at the tumor site and thus interaction probability, resulting in higher photon signal of Ga radioisotope used in positron emission tomography. In vitro ligand-receptor binding evaluation of the radiolabeled compound has showed increased retention of the positron emitter radionuclide Ga in the presence of the gold nanoparticles. [ABSTRACT FROM AUTHOR]

Recent advances and large-scale use of hybrid imaging modalities like PET-CT have led to the necessity of improving nano-drug carriers that can facilitate both functional and metabolic screening in nuclear medicine applications. In this study, we focused on the evaluation of four potential imaging nanoparticle structures labelled with the 68Ga positron emitter. For this purpose, we functionalized NHS-activated PEG-gold nanoparticles with 68Ga-DOTA-Neuromedin B, 68Ga-DOTA-PEG(4)-BBN(7-14), 68Ga-DOTA-NT and 68Ga-DOTA-Neuromedin N. In vitro binding kinetics and specific binding to human HT-29 colon carcinoma cells and DU-145 prostate carcinoma cells respectively were assessed, over 75% retention being obtained in the case of 68Ga-DOTA-PEG(4)-BBN(7-14)-AuNP in prostate tumour cells and over 50% in colon carcinoma cells. Biodistribution in NU/J mice highlighted a three-fold uptake increase in tumours at 30 min post-injection of 68Ga-DOTA-NT-AuNP and 68Ga-DOTA-PEG(4)-BBN(7-14)-AuNP compared to 68Ga-DOTA-NT and 68Ga-DOTA-PEG(4)-BBN(7-14) respectively, therewith fast distribution in prostate and colon tumours and minimum accumulation in non-targeted tissues. [ABSTRACT FROM AUTHOR]